Ocrevus 300mg Injection (Ocrelizumab) – Complete Product Description

Ocrevus 300mg Injection (Ocrelizumab) is a prescription medicine manufactured by Roche and used as a targeted immunotherapy for adults with specific forms of multiple sclerosis (MS). Ocrevus contains ocrelizumab, a recombinant humanized monoclonal antibody that selectively targets CD20-positive B cells, a type of immune cell involved in the inflammatory processes associated with multiple sclerosis.

By binding to CD20 on B cells, ocrelizumab helps reduce the number and activity of these cells. This can decrease abnormal immune-system activity that contributes to inflammation and damage in the central nervous system.

Ocrevus 300mg is supplied as a concentrate for solution for intravenous infusion. The product listed here is manufactured by Roche and supplied in a pack size of 1 injection/vial.

Ocrevus 300mg Injection – Product Information

Brand Name: Ocrevus
Active Ingredient: Ocrelizumab
Strength: 300mg
Dosage Form: Concentrate for solution for intravenous infusion
Route of Administration: Intravenous (IV) infusion
Manufacturer: Roche
Pack Size: 1 injection/vial
Drug Class: CD20-directed monoclonal antibody
Therapeutic Class: Immunomodulatory / Multiple sclerosis treatment
Prescription Status: Prescription medicine

Ocrevus is a specialized biological medicine and should be prepared and administered by appropriately trained healthcare professionals.

What Is Ocrevus 300mg Injection Used For?

Ocrevus (Ocrelizumab) is approved for the treatment of adults with specific forms of multiple sclerosis, including:

• Relapsing forms of multiple sclerosis
• Clinically isolated syndrome (CIS)
• Relapsing-remitting multiple sclerosis (RRMS)
• Active secondary progressive multiple sclerosis (SPMS)
• Primary progressive multiple sclerosis (PPMS)

The exact approved indication can vary by country and regulatory authority. Your neurologist will determine whether Ocrevus is appropriate based on your diagnosis, disease activity, medical history and treatment goals.

Ocrevus for Relapsing Multiple Sclerosis

Ocrevus is used for adults with relapsing forms of multiple sclerosis. These conditions can involve episodes of neurological symptoms followed by periods of partial or complete recovery.

By targeting CD20-positive B cells, ocrelizumab helps reduce immune-mediated inflammation associated with MS and can reduce disease activity in appropriately selected patients.

Ocrevus for Primary Progressive Multiple Sclerosis

Ocrevus is also used for adults with primary progressive multiple sclerosis (PPMS) in appropriate patients.

PPMS is characterized by a gradual worsening of neurological function rather than clearly defined relapses and remissions. Ocrelizumab is an important disease-modifying therapy for eligible patients with PPMS.

How Does Ocrevus (Ocrelizumab) Work?

Ocrevus contains ocrelizumab, a monoclonal antibody that targets CD20, a protein expressed on the surface of specific B lymphocytes.

B cells are involved in immune responses and can contribute to inflammation in multiple sclerosis. Ocrelizumab binds to CD20-positive B cells and promotes their depletion through immune-mediated mechanisms.

Reducing these B cells can help decrease inflammatory activity within the central nervous system and may slow disease progression and reduce relapse activity in appropriate patients.

Ocrevus is therefore considered a B-cell-depleting disease-modifying therapy rather than a conventional immunosuppressive medicine.

Ocrevus 300mg Dose and Administration

Ocrevus 300mg is administered through intravenous infusion by a qualified healthcare professional.

The initial course generally consists of two 300mg intravenous infusions given two weeks apart. Subsequent treatment is generally administered as a single 600mg intravenous infusion every six months, according to the prescribed treatment regimen.

Before each infusion, healthcare professionals may administer premedication to reduce the risk and severity of infusion-related reactions.

The exact treatment schedule should always be determined by the treating neurologist.

Do not self-inject Ocrevus 300mg.

Premedication Before Ocrevus Infusion

Because infusion-related reactions can occur with ocrelizumab, patients are generally given appropriate premedication before the infusion.

This may include:

• A corticosteroid
• An antihistamine
• Additional medication when clinically appropriate

The healthcare professional will determine the appropriate premedication and monitoring plan.

Common Side Effects of Ocrevus 300mg

Like all medicines, Ocrevus can cause side effects. The most common reactions are associated with infusion and immune-system changes.

Possible side effects include:

• Infusion-related reactions
• Skin rash
• Itching
• Headache
• Fever
• Chills
• Fatigue
• Nausea
• Redness or swelling
• Upper respiratory tract infections
• Respiratory infections

Patients should tell their healthcare provider about persistent, severe or unusual symptoms.

Serious Side Effects and Risks

Infusion-Related Reactions

Infusion reactions are among the most common adverse effects associated with Ocrevus.

Symptoms may include:

• Itching
• Rash
• Redness
• Throat irritation
• Difficulty breathing
• Flushing
• Headache
• Dizziness
• Nausea
• Rapid heartbeat
• Changes in blood pressure

Patients are monitored during and after the infusion. Severe reactions require immediate medical management.

Infections

Because ocrelizumab reduces certain B cells, it can affect immune responses and may increase the risk of infections.

Patients should inform their healthcare provider if they develop:

• Fever
• Persistent cough
• Severe sore throat
• Recurrent infections
• Unexplained weakness
• Other signs of infection

Hepatitis B Reactivation

Patients should be evaluated for hepatitis B virus (HBV) infection before starting Ocrevus.

Those with current or previous HBV infection may require specialist evaluation and monitoring.

Reduced Immunoglobulin Levels

Ocrelizumab treatment can reduce immunoglobulin levels in some patients. Healthcare professionals may monitor immunoglobulin levels, particularly in patients who experience recurrent infections.

Progressive Multifocal Leukoencephalopathy

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection that has been reported in patients receiving medicines that affect the immune system.

Patients should immediately report new neurological symptoms such as changes in vision, coordination, strength, speech or cognition.

Precautions Before Using Ocrevus

Before receiving Ocrevus 300mg, tell your healthcare provider if you have:

• Current or recent infection
• A history of recurrent infections
• Hepatitis B infection or previous HBV exposure
• A weakened immune system
• Low immunoglobulin levels
• A history of cancer
• Any known allergy to ocrelizumab or other monoclonal antibodies

Your doctor should also know about all medicines, supplements and other treatments you are currently taking.

Vaccinations Before Ocrevus Treatment

Vaccination status should be reviewed before starting Ocrevus.

Certain vaccines may need to be administered before treatment because immune responses can be reduced following B-cell depletion.

Live or live-attenuated vaccines should generally be avoided during treatment and until appropriate immune recovery occurs, according to medical advice.

Patients should discuss their vaccination schedule with their neurologist before starting Ocrevus.

Ocrevus During Pregnancy

Women who are pregnant, planning pregnancy or capable of becoming pregnant should discuss Ocrevus treatment with their healthcare provider.

Because ocrelizumab affects B cells, treatment may have implications for the developing fetus and newborn’s immune system.

Your healthcare professional will discuss the potential risks and benefits and advise on appropriate contraception and pregnancy planning.

Ocrevus and Breastfeeding

Ocrelizumab may pass into breast milk in small amounts. Patients should discuss breastfeeding with their doctor before receiving Ocrevus.

The healthcare provider will consider the mother’s treatment needs and potential risks to the infant when providing individualized advice.

Ocrevus 300mg Storage

Ocrevus is a biological medicine that requires controlled storage and handling.

The unopened vial should be stored under the manufacturer’s recommended refrigerated conditions and protected from light.

Do not freeze or shake Ocrevus.

Once prepared, the diluted infusion solution must be handled according to approved pharmaceutical procedures and administered within the appropriate time period.

Ocrevus should only be prepared and administered by trained healthcare professionals.

Ocrevus 300mg Injection Price in Pakistan

The Ocrevus 300mg Injection price in Pakistan may vary depending on availability, supplier, import costs, exchange rates and prevailing market conditions.

For the latest Ocrevus 300mg price in Pakistan, customers can contact MedicineWalyDost.com to check current availability and pricing.

Specialized biological medicines may have changing prices, so customers should confirm the current price before ordering.

Why Choose Ocrevus 300mg Injection?

Ocrevus contains ocrelizumab, a targeted CD20-directed monoclonal antibody specifically developed for the treatment of appropriate forms of multiple sclerosis.

Its B-cell-targeted mechanism provides a disease-modifying approach for adults with relapsing forms of MS and primary progressive MS when clinically appropriate.

The Roche-manufactured Ocrevus 300mg presentation is supplied for intravenous infusion under professional medical supervision.

Frequently Asked Questions About Ocrevus 300mg

What is Ocrevus 300mg Injection?

Ocrevus 300mg Injection is a prescription biological medicine containing ocrelizumab, a CD20-directed monoclonal antibody used as a disease-modifying treatment for certain forms of multiple sclerosis.

What is the generic name of Ocrevus?

The generic name is ocrelizumab.

Who manufactures Ocrevus 300mg?

The manufacturer of the product listed here is Roche.

What is the pack size of Ocrevus 300mg?

The pack size for this product is 1 injection/vial.

How is Ocrevus 300mg administered?

Ocrevus 300mg is administered by intravenous infusion under the supervision of a qualified healthcare professional.

How often is Ocrevus 300mg given?

The initial treatment course generally consists of two 300mg infusions separated by two weeks. Subsequent treatment generally uses a 600mg infusion every six months, according to the prescribed treatment plan.

What is Ocrevus used for?

Ocrevus is used for adults with selected relapsing forms of multiple sclerosis and primary progressive multiple sclerosis, depending on the applicable indication.

Is Ocrevus a chemotherapy medicine?

No. Ocrevus is a monoclonal antibody and disease-modifying immunotherapy that targets CD20-positive B cells.

Does Ocrevus cure multiple sclerosis?

Ocrevus is a disease-modifying treatment that can reduce disease activity and progression in appropriate patients. It is not considered a cure for multiple sclerosis.

Can Ocrevus be purchased without a prescription?

Ocrevus is a specialized prescription biological medicine and should only be used under the supervision of a qualified neurologist or healthcare professional.

Order Ocrevus 300mg Injection in Pakistan

Looking for Ocrevus 300mg Injection (Ocrelizumab) by Roche in Pakistan?

MedicineWalyDost.com provides access to specialized prescription medicines and biological products. Contact us to check the latest Ocrevus 300mg price, availability and ordering information.

Before ordering, confirm the brand, strength, active ingredient, manufacturer, pack size and prescription requirements with your doctor or pharmacist.

Order Ocrevus 300mg Injection from MedicineWalyDost.com and contact us today for current availability and pricing.

Important Medical Disclaimer

Ocrevus 300mg Injection is a prescription medicine used for specific forms of multiple sclerosis. This product description is provided for educational and e-commerce purposes only and does not replace professional medical advice. Ocrevus should be prescribed, prepared and administered by qualified healthcare professionals. Do not start, stop or change treatment without consulting your neurologist.